B
Bull
Bull · 25%RAIN
$4.56
Precio del escenario
$0.985
-0.024 (-2.48%)Al cierre
Loading chart…
- High
- 1.040
- Open
- 1.030
- VWAP
- 1.00
- Vol
- 108.89K
- Mkt Cap
- 44.03M
- Low
- 0.970
- Amount
- 108.71K
- EV/EBITDA, TTM
- 0.00
Rain Enhancement Technologies Holdco, Inc. is engaged in developing rainfall generation technology. The Company is focused on developing, manufacturing and commercializing ionization rainfall generation technology to provide additional rainfall for industries, supranational organizations, countries and localities. It focuses on building its core platform with software, meteorology, hardware, product design and operations to make rainfall generation more dependable. It focuses on improving on existing rainfall generation technologies by introducing measurement tools, including automation technology, rain gauges, and weather stations. The rainfall generation platform ionizes the surrounding air similar to how air purifiers work. It intends to enhance agricultural, industrial and household water supplies for all the communities in which it operates by developing technology and services to serve governmental and commercial clients’ needs.
AI analysis of Rain Enhancement Technologies Holdco Inc (RAIN)
sellRain Oncology Inc. is not a good buy right now due to its significant financial losses and lack of revenue. The stock has a current price of 0.98, a year-to-date change of -80.30%, and a forward P/E ratio of 0, indicating no expected earnings growth. The main risk is its negative net income of -3,246,657 in the latest quarter, which raises concerns about its financial viability.
Métricas de valoración
The current forward P/E ratio for Rain Enhancement Technologies Holdco Inc (RAIN) is 0.00, compared to its 5-year average forward P/E of -0.88.
Alphio AI Price Scenarios for RAIN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding RAIN
Cronología de eventos
Noticias
1.008-07GlobenewswireRain Oncology CEO to Participate in Healthcare Conference
3.501-08GlobenewswireRainPoint Launches $111.99 All-in-One Smart Irrigation System
8.512-31BenzingaFuelCell Energy Files for $200 Million Stock Offering, Shares Drop 8.9%
9.512-16BenzingaB. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
7.012-12GlobenewswireRain Bird Reports Cybersecurity Incident Affecting Over 20,000 Individuals
RAIN FAQ — answered by Alphio AI
Rain Enhancement Technologies Holdco, Inc. is engaged in developing rainfall generation technology. The Company is focused on developing, manufacturing and commercializing ionization rainfall generation technology to provide additional rainfall for industries, supranational organizations, countries and localities. It focuses on building its core platform with software, meteorology, hardware, product design and operations to make rainfall generation more dependable. It focuses on improving on existing rainfall generation technologies by introducing measurement tools, including automation technology, rain gauges, and weather stations. The rainfall generation platform ionizes the surrounding air similar to how air purifiers work. It intends to enhance agricultural, industrial and household water supplies for all the communities in which it operates by developing technology and services to serve governmental and commercial clients’ needs. It operates in the Industrials sector (PHARMACEUTICAL PREPARATIONS industry).
Rain Oncology Inc. is not a good buy right now due to its significant financial losses and lack of revenue. The stock has a current price of 0.98, a year-to-date change of -80.30%, and a forward P/E ratio of 0, indicating no expected earnings growth. The main risk is its negative net income of -3,246,657 in the latest quarter, which raises concerns about its financial viability.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.